Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
Kaiser Permanente
Duke University
Washington University School of Medicine
Arvinas Inc.
University of Colorado, Denver
City of Hope Medical Center